Ocugen Chairman and CEO to present at Abu Dhabi Family Office Summit
February 26 2024 - 8:30AM
Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a
biotechnology company focused on discovering, developing, and
commercializing novel gene and cell therapies and vaccines, today
announced that Dr. Shankar Musunuri, Chairman, Chief Executive
Officer and Co-Founder of Ocugen will present at the Abu Dhabi
Family Office (ADFO) Summit being held February 29—March 1, 2024 at
the Saadiyat Rotana Resort and Villas in Abu Dhabi, United Arab
Emirates.
“I’m honored to be an invited speaker among the prestigious
gathering at the ADFO Summit,” said Dr. Musunuri. “This is an
excellent opportunity to share more about the potential of Ocugen’s
novel modifier gene therapy platform in an area of the world where
there’s a high incidence of blindness diseases. I’m confident that
this event will help raise awareness while also making important
introductions for Ocugen.”
Details of the presentation are as follows:
Interactive Panel 7—How family offices are drawn towards
longevity, healthcare, life sciences and wellness as they come to
terms with family challenges and the impact of modern lifestyle
Date: Friday, March 1, 2024Presentation Time: 3:05-3:45 p.m.
GSTLocation: Saadiyat Rotana Resort and Villas in Abu Dhabi, United
Arab Emirates
“It is a pleasure to host Ocugen in Abu Dhabi to educate the UAE
and the Middle East on modifier gene therapy,” said Obediah Ayton,
ADFO Summit Chairman. “Abu Dhabi is currently seeking many experts
from around the word to explore R&D locally within the UAE.
Experienced businesses like Ocugen can deliver much potential for
the UAE towards their 2030 plan. Dr. Musunuri will join well-known
family offices like Tamer Group, Bait Al Batterjee Holding, and
others to discuss the future of life sciences and healthcare in the
UAE.”
This is the second public ADFO Summit, an event focused on
creating new opportunities for partnership, investment, innovation
and social good. Dr. Musunuri is among the industry speakers that
have been invited to participate in the summit, joining
representatives from family offices and institutional funds.
About Ocugen, Inc. Ocugen, Inc. is a
biotechnology company focused on discovering, developing, and
commercializing novel gene and cell therapies, biologics, and
vaccines that improve health and offer hope for patients across the
globe. We are making an impact on patients’ lives through
courageous innovation—forging new scientific paths that harness our
unique intellectual and human capital. Our breakthrough modifier
gene therapy platform has the potential to treat multiple retinal
diseases with a single product, and we are advancing research in
infectious diseases to support public health and orthopedic
diseases to address unmet medical needs. Discover more
at www.ocugen.com and follow us on X and LinkedIn.
Forward-Looking Statements This press
release contains forward-looking statements within the meaning of
The Private Securities Litigation Reform Act of 1995, which are
subject to risks and uncertainties. We may, in some cases, use
terms such as “predicts,” “believes,” “potential,” “proposed,”
“continue,” “estimates,” “anticipates,” “expects,” “plans,”
“intends,” “may,” “could,” “might,” “will,” “should,” or other
words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. Such statements are
subject to numerous important factors, risks, and uncertainties
that may cause actual events or results to differ materially from
our current expectations. These and other risks and uncertainties
are more fully described in our periodic filings with the
Securities and Exchange Commission (SEC), including the risk
factors described in the section entitled “Risk Factors” in the
quarterly and annual reports that we file with the SEC. Any
forward-looking statements that we make in this press release speak
only as of the date of this press release. Except as required by
law, we assume no obligation to update forward-looking statements
contained in this press release whether as a result of new
information, future events, or otherwise, after the date of this
press release.
Contact: Tiffany Hamilton Head of
Communications Tiffany.Hamilton@ocugen.com
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Apr 2023 to Apr 2024